-
2
-
-
80054964173
-
Clinical diagnosis of Alzheimers disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimers Disease
-
McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimers disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimers Disease. Neurology 2011;77(4):333
-
(2011)
Neurology
, vol.77
, Issue.4
, pp. 333
-
-
McKhann, G.1
Drachman, D.2
Folstein, M.3
-
3
-
-
79956076567
-
Introduction to the recommendations from the National Institute on Aging-Alzheimers Association workgroups on diagnostic guidelines for Alzheimers disease
-
Jack CR Jr, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimers Association workgroups on diagnostic guidelines for Alzheimers disease. Alzheimers Dement J Alzheimers Association 2011;7(3):257-62
-
(2011)
Alzheimers Dement J Alzheimers Association
, vol.7
, Issue.3
, pp. 257-62
-
-
Jack, Jr.C.R.1
Albert, M.S.2
Knopman, D.S.3
-
5
-
-
48749109915
-
The ART of loss: Abeta imaging in the evaluation of Alzheimers disease and other dementias
-
Villemagne V, Fodero-Tavoletti M, Pike K, et al. The ART of loss: Abeta imaging in the evaluation of Alzheimers disease and other dementias. Mol Neurobiol 2008;38(1):1-15
-
(2008)
Mol Neurobiol
, vol.38
, Issue.1
, pp. 1-15
-
-
Villemagne, V.1
Fodero-Tavoletti, M.2
Pike, K.3
-
6
-
-
70350266228
-
Amyloid imaging in aging and dementia: Testing the amyloid hypothesis in vivo
-
Rabinovici GD, Jagust WJ. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol 2009;21(1):117-28
-
(2009)
Behav Neurol
, vol.21
, Issue.1
, pp. 117-28
-
-
Rabinovici, G.D.1
Jagust, W.J.2
-
7
-
-
68449090629
-
Update on amyloid imaging: From healthy aging to Alzheimers disease
-
Wolk D, Klunk W. Update on amyloid imaging: from healthy aging to Alzheimers disease. Curr Neurol Neurosci Rep 2009;9(5):345-52
-
(2009)
Curr Neurol Neurosci Rep
, vol.9
, Issue.5
, pp. 345-52
-
-
Wolk, D.1
Klunk, W.2
-
8
-
-
0035902875
-
Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain
-
DOI 10.1016/S0024-3205(01)01232-2, PII S0024320501012322
-
Klunk WE, Wang Y, Huang G-F, et al. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci 2001;69(13):1471-84 (Pubitemid 32786721)
-
(2001)
Life Sciences
, vol.69
, Issue.13
, pp. 1471-1484
-
-
Klunk, W.E.1
Wang, Y.2
Huang, G.-F.3
Debnath, M.L.4
Holt, D.P.5
Mathis, C.A.6
-
9
-
-
10744232413
-
Imaging brain amyloid in Alzheimers disease with Pittsburgh compound-B
-
DOI 10.1002/ana.20009
-
Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimers disease with Pittsburgh compound-B. Ann Neurol 2004;55(3):306-19 (Pubitemid 38269583)
-
(2004)
Annals of Neurology
, vol.55
, Issue.3
, pp. 306-319
-
-
Klunk, W.E.1
Engler, H.2
Nordberg, A.3
Wang, Y.4
Blomqvist, G.5
Holt, D.P.6
Bergstrom, M.7
Savitcheva, I.8
Huang, G.-F.9
Estrada, S.10
Ausen, B.11
Debnath, M.L.12
Barletta, J.13
Price, J.C.14
Sandell, J.15
Lopresti, B.J.16
Wall, A.17
Koivisto, P.18
Antoni, G.19
Mathis, C.A.20
Langstrom, B.21
more..
-
10
-
-
56749112290
-
The future of amyloid-beta imaging: A tale of radionuclides and tracer proliferation
-
Klunk WE, Mathis CA. The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation. Curr Opin Neurol 2008;21(6):683-7
-
(2008)
Curr Opin Neurol
, vol.21
, Issue.6
, pp. 683-7
-
-
Klunk, W.E.1
Mathis, C.A.2
-
11
-
-
79958033200
-
The importance of appropriate partial volume correction for PET quantification in Alzheimers disease
-
Thomas BA, Erlandsson K, Modat M, et al. The importance of appropriate partial volume correction for PET quantification in Alzheimers disease. Eur J Nucl Med Mol Imaging 2011;38(6):1104-19
-
(2011)
Eur J Nucl Med Mol Imaging
, vol.38
, Issue.6
, pp. 1104-19
-
-
Thomas, B.A.1
Erlandsson, K.2
Modat, M.3
-
12
-
-
77956384880
-
18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial
-
Vandenberghe R, Van Laere K, Ivanoiu A, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 2010;68(3):319-29
-
(2010)
Ann Neurol
, vol.68
, Issue.3
, pp. 319-29
-
-
Vandenberghe, R.1
Van Laere, K.2
Ivanoiu, A.3
-
13
-
-
68249141258
-
Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease
-
Nelissen N, Van Laere K, Thurfjell L, et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med 2009;50(8):1251-9
-
(2009)
J Nucl Med
, vol.50
, Issue.8
, pp. 1251-9
-
-
Nelissen, N.1
Van Laere, K.2
Thurfjell, L.3
-
14
-
-
66149104129
-
Whole-body biodistribution and radiation dosimetry of 18F-GE067: A radioligand for in vivo brain amyloid imaging
-
Koole M, Lewis DM, Buckley C, et al. Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. J Nucl Med 2009;50(5):818-22
-
(2009)
J Nucl Med
, vol.50
, Issue.5
, pp. 818-22
-
-
Koole, M.1
Lewis, D.M.2
Buckley, C.3
-
15
-
-
77952552594
-
Whole-body biodistribution and brain PET imaging with [18F]AV-45 a novel amyloid imaging agent - A pilot study
-
Lin K-J, Hsu W-C, Hsiao I-T, et al. Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent - a pilot study. Nucl Med Biol 2010;37(4):497-508
-
(2010)
Nucl Med Biol
, vol.37
, Issue.4
, pp. 497-508
-
-
Lin, K.-J.1
Hsu, W.-C.2
Hsiao, I.-T.3
-
16
-
-
77953937194
-
In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (flobetapir F 18)
-
Wong DF, Rosenberg PB, Zhou Y, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (flobetapir F 18). J Nucl Med 2010;51(6):913-20
-
(2010)
J Nucl Med
, vol.51
, Issue.6
, pp. 913-20
-
-
Wong, D.F.1
Rosenberg, P.B.2
Zhou, Y.3
-
17
-
-
70350716476
-
Preclinical properties of 18F-AV-45: A PET agent for Abeta plaques in the brain
-
Choi SR, Golding G, Zhuang Z, et al. Preclinical properties of 18F-AV-45: A PET agent for Abeta plaques in the brain. J Nucl Med 2009;50(11):1887-94
-
(2009)
J Nucl Med
, vol.50
, Issue.11
, pp. 1887-94
-
-
Choi, S.R.1
Golding, G.2
Zhuang, Z.3
-
18
-
-
38149081191
-
Imaging of amyloid-beta in Alzheimers disease with 18F-BAY94-9172, a novel PET tracer: Proof of mechanism
-
Rowe CC, Ackerman U, Browne W, et al. Imaging of amyloid-beta in Alzheimers disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008;7(2):129-35
-
(2008)
Lancet Neurol
, vol.7
, Issue.2
, pp. 129-35
-
-
Rowe, C.C.1
Ackerman, U.2
Browne, W.3
-
19
-
-
80051688987
-
Amyloid imaging with 18F-florbetaben in Alzheimer disease and other dementias
-
Villemagne VL, Ong K, Mulligan RS, et al. Amyloid imaging with 18F-florbetaben in Alzheimer disease and other dementias. J Nucl Med 2011;52(8):1210-17
-
(2011)
J Nucl Med
, vol.52
, Issue.8
, pp. 1210-17
-
-
Villemagne, V.L.1
Ong, K.2
Mulligan, R.S.3
-
20
-
-
77954338544
-
Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand
-
Jureus A, Swahn B-M, Sandell J, et al. Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand. J Neurochem 2010;114(3):784-94
-
(2010)
J Neurochem
, vol.114
, Issue.3
, pp. 784-94
-
-
Jureus, A.1
Swahn, B.-M.2
Sandell, J.3
-
21
-
-
15944366880
-
11C]SB-13 PET
-
DOI 10.1176/appi.ajgp.12.6.584
-
Verhoeff NP, Wilson AA, Takeshita S, et al. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB- 13 PET. Am J Geriatr Psychiatry 2004;12(6):584-95 (Pubitemid 41031060)
-
(2004)
American Journal of Geriatric Psychiatry
, vol.12
, Issue.6
, pp. 584-595
-
-
Verhoeff, N.P.L.G.1
Wilson, A.A.2
Takeshita, S.3
Trop, L.4
Hussey, D.5
Singh, K.6
Kung, H.F.7
Kung, M.-P.8
Houle, S.9
-
22
-
-
0037195577
-
IMPY: An improved thioflavin-T derivative for in vivo labeling of β-amyloid plaques
-
DOI 10.1016/S0006-8993(02)03436-4, PII S0006899302034364
-
Kung M-P, Hou C, Zhuang Z-P, et al. IMPY: an improved thioflavin-T derivative for in vivo labeling of [beta]-amyloid plaques. Brain Res 2002;956(2):202-10 (Pubitemid 35351385)
-
(2002)
Brain Research
, vol.956
, Issue.2
, pp. 202-210
-
-
Kung, M.-P.1
Hou, C.2
Zhuang, Z.-P.3
Zhang, B.4
Skovronsky, D.5
Trojanowski, J.Q.6
Lee, V.M.-Y.7
Kung, H.F.8
-
23
-
-
34547839770
-
11C]MeS-IMPY, a candidate radioligand for β-amyloid plaques
-
DOI 10.1016/j.nucmedbio.2007.06.002, PII S096980510700162X
-
Seneca N, Cai L, Liow J-S, et al. Brain and whole-body imaging in nonhuman primates with [11C]MeS-IMPY, a candidate radioligand for [beta]-amyloid plaques. Nucl Med Biol 2007;34(6):681-9 (Pubitemid 47248291)
-
(2007)
Nuclear Medicine and Biology
, vol.34
, Issue.6
, pp. 681-689
-
-
Seneca, N.1
Cai, L.2
Liow, J.-S.3
Zoghbi, S.S.4
Gladding, R.L.5
Hong, J.6
Pike, V.W.7
Innis, R.B.8
-
24
-
-
33845707784
-
PET of brain amyloid and tau in mild cognitive impairment
-
DOI 10.1056/NEJMoa054625
-
Small GW, Kepe V, Ercoli LM, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 2006;355(25):2652-63 (Pubitemid 44969124)
-
(2006)
New England Journal of Medicine
, vol.355
, Issue.25
, pp. 2652-2663
-
-
Small, G.W.1
Kepe, V.2
Ercoli, L.M.3
Siddarth, P.4
Bookheimer, S.Y.5
Miller, K.J.6
Lavretsky, H.7
Burggren, A.C.8
Cole, G.M.9
Vinters, H.V.10
Thompson, P.M.11
Huang, S.-C.12
Satyamurthy, N.13
Phelps, M.E.14
Barrio, J.R.15
-
25
-
-
0035893245
-
Binding characteristics of radiofluorinated 6-dialkylamino-2- naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimers disease
-
Agdeppa ED, Kepe V, Liu J, et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimers disease. J Neurosci 2001;21(24):RC189-RC89
-
(2001)
J Neurosci
, vol.21
, Issue.24
-
-
Agdeppa, E.D.1
Kepe, V.2
Liu, J.3
-
26
-
-
0041335200
-
Molecular-imaging probe 2-(1-{6-[(2-fluoroethyl)(methyl) amino]-2-naphthyl}ethylidene) malononitrile labels prion plaques in vitro
-
Bresjanac M, Smid LM, Vovko TD, et al. Molecular-imaging probe 2-(1-{6- [(2-fluoroethyl)(methyl) amino]-2- naphthyl}ethylidene) malononitrile labels prion plaques in vitro. J Neurosci 2003;23(22):8029-33 (Pubitemid 37082455)
-
(2003)
Journal of Neuroscience
, vol.23
, Issue.22
, pp. 8029-8033
-
-
Bresjanac, M.1
Smid, L.M.2
Vovko, T.D.3
Petric, A.4
Barrio, J.R.5
Popovic, M.6
-
27
-
-
33745028473
-
The 2,6-disubstituted naphthalene derivative FDDNP labeling reliably predicts Congo red birefringence of protein deposits in brain sections of selected human neurodegenerative diseases
-
DOI 10.1111/j.1750-3639.2006.00006.x
-
Smid LM, Vovko TD, Popovic M, et al. The 2,6-disubstituted naphthalene derivative FDDNP labeling reliably predicts Congo red birefringence of protein deposits in brain sections of selected human neurodegenerative diseases. Brain Pathol 2006;16(2):124-30 (Pubitemid 43876472)
-
(2006)
Brain Pathology
, vol.16
, Issue.2
, pp. 124-130
-
-
Smid, L.M.1
Vovko, T.D.2
Popovic, M.3
Petric, A.4
Kepe, V.5
Barrio, J.R.6
Vidmar, G.7
Bresjanac, M.8
-
28
-
-
53049093702
-
Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimers disease
-
Shin J, Lee S-Y, Kim S-H, et al. Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimers disease. Neuroimage 2008;43(2):236-44
-
(2008)
Neuroimage
, vol.43
, Issue.2
, pp. 236-44
-
-
Shin, J.1
Lee, S.-Y.2
Kim, S.-H.3
-
29
-
-
77955707891
-
Voxel-based analysis of Alzheimers disease PET imaging using a triplet of radiotracers: PIB FDDNP and FDG
-
Shin J, Lee S-Y, Kim SJ, et al. Voxel-based analysis of Alzheimers disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG. Neuroimage 2010;52(2):488-96
-
(2010)
Neuroimage
, vol.52
, Issue.2
, pp. 488-96
-
-
Shin, J.1
Lee, S.-Y.2
Kim, S.J.3
-
30
-
-
34248579112
-
2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy) benzoxazole: A novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients
-
DOI 10.2967/jnumed.106.037556
-
Kudo Y, Okamura N, Furumoto S, et al. 2-(2-[2-dimethylaminothiazol-5-yl] ethenyl)-6- (2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimers disease patients. J Nucl Med 2007;48(4):553-61 (Pubitemid 47571409)
-
(2007)
Journal of Nuclear Medicine
, vol.48
, Issue.4
, pp. 553-561
-
-
Kudo, Y.1
Okamura, N.2
Furumoto, S.3
Tashiro, M.4
Furukawa, K.5
Maruyama, M.6
Itoh, M.7
Iwata, R.8
Yanai, K.9
Arai, H.10
-
31
-
-
77952090854
-
In vivo detection of prion amyloid plaques using [11C]BF-227 PET
-
Okamura N, Shiga Y, Furumoto S, et al. In vivo detection of prion amyloid plaques using [11C]BF-227 PET. Eur J Nucl Med Mol Imaging 2010;37(5):934-41
-
(2010)
Eur J Nucl Med Mol Imaging
, vol.37
, Issue.5
, pp. 934-41
-
-
Okamura, N.1
Shiga, Y.2
Furumoto, S.3
-
32
-
-
77952982672
-
In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2- dimethylaminothiazol-5-yl)ethenyl]-6-[2- (fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy
-
Kikuchi A, Takeda A, Okamura N, et al. In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2- dimethylaminothiazol- 5-yl)ethenyl]-6-[2- (fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy. Brain 2010;133(6):1772-8
-
(2010)
Brain
, vol.133
, Issue.6
, pp. 1772-8
-
-
Kikuchi, A.1
Takeda, A.2
Okamura, N.3
-
33
-
-
77952369391
-
Amyloid PET in mild cognitive impairment and Alzheimers disease with BF-227: Comparison to FDG-PET
-
Furukawa K, Okamura N, Tashiro M, et al. Amyloid PET in mild cognitive impairment and Alzheimers disease with BF-227: comparison to FDG-PET. J Neurol 2010;257(5):721-7
-
(2010)
J Neurol
, vol.257
, Issue.5
, pp. 721-7
-
-
Furukawa, K.1
Okamura, N.2
Tashiro, M.3
-
34
-
-
68549085069
-
In vitro characterisation of BF227 binding to [alpha]-synuclein/Lewy bodies
-
Fodero-Tavoletti MT, Mulligan RS, Okamura N, et al. In vitro characterisation of BF227 binding to [alpha]-synuclein/Lewy bodies. Eur J Pharmacol 2009;617(1-3):54-8
-
(2009)
Eur J Pharmacol
, vol.617
, Issue.1-3
, pp. 54-8
-
-
Fodero-Tavoletti, M.T.1
Mulligan, R.S.2
Okamura, N.3
-
35
-
-
69549089908
-
Comparison study of amyloid PET and voxel-based morphometry analysis in mild cognitive impairment and Alzheimers disease
-
Waragai M, Okamura N, Furukawa K, et al. Comparison study of amyloid PET and voxel-based morphometry analysis in mild cognitive impairment and Alzheimers disease. J Neurol Sci 2009;285(1-2):100-8
-
(2009)
J Neurol Sci
, vol.285
, Issue.1-2
, pp. 100-8
-
-
Waragai, M.1
Okamura, N.2
Furukawa, K.3
-
36
-
-
43849083580
-
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
-
DOI 10.1093/brain/awn016
-
Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimers disease. Brain 2008;131(6):1630-45 (Pubitemid 351806448)
-
(2008)
Brain
, vol.131
, Issue.6
, pp. 1630-1645
-
-
Ikonomovic, M.D.1
Klunk, W.E.2
Abrahamson, E.E.3
Mathis, C.A.4
Price, J.C.5
Tsopelas, N.D.6
Lopresti, B.J.7
Ziolko, S.8
Bi, W.9
Paljug, W.R.10
Debnath, M.L.11
Hope, C.E.12
Isanski, B.A.13
Hamilton, R.L.14
DeKosky, S.T.15
-
37
-
-
79951520786
-
In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults
-
Sojkova J, Driscoll I, Iacono D, et al. In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. Arch Neurol 2011;68(2):232-40
-
(2011)
Arch Neurol
, vol.68
, Issue.2
, pp. 232-40
-
-
Sojkova, J.1
Driscoll, I.2
Iacono, D.3
-
38
-
-
78751546481
-
Use of florbetapir-PET for imaging beta-amyloid pathology
-
Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011;305(3):275-83
-
(2011)
JAMA
, vol.305
, Issue.3
, pp. 275-83
-
-
Clark, C.M.1
Schneider, J.A.2
Bedell, B.J.3
-
39
-
-
78751532097
-
Mapping out biomarkers for Alzheimer disease
-
Breteler MMB. Mapping out biomarkers for Alzheimer disease. JAMA 2011;305(3):304-5
-
(2011)
JAMA
, vol.305
, Issue.3
, pp. 304-5
-
-
Mmb, B.1
-
41
-
-
34948819200
-
Imaging of amyloid burden and distribution in cerebral amyloid angiopathy
-
DOI 10.1002/ana.21164
-
Johnson KA, Gregas M, Becker JA, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 2007;62(3):229-34 (Pubitemid 47525398)
-
(2007)
Annals of Neurology
, vol.62
, Issue.3
, pp. 229-234
-
-
Johnson, K.A.1
Gregas, M.2
Becker, J.A.3
Kinnecom, C.4
Salat, D.H.5
Moran, E.K.6
Smith, E.E.7
Rosand, J.8
Rentz, D.M.9
Klunk, W.E.10
Mathis, C.A.11
Price, J.C.12
DeKosky, S.T.13
Fischman, A.J.14
Greenberg, S.M.15
-
42
-
-
74049124939
-
In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia
-
Burack MA, Hartlein J, Flores HP, et al. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology 2010;74(1):77-84
-
(2010)
Neurology
, vol.74
, Issue.1
, pp. 77-84
-
-
Burack, M.A.1
Hartlein, J.2
Flores, H.P.3
-
43
-
-
79960996008
-
Ante mortem amyloid imaging and beta-amyloid pathology in a case with dementia with Lewy bodies
-
In press
-
Kantarci K, Yang C, Schneider JA, et al. Ante mortem amyloid imaging and beta-amyloid pathology in a case with dementia with Lewy bodies. Neurobiol Aging 2010; In press
-
(2010)
Neurobiol Aging
-
-
Kantarci, K.1
Yang, C.2
Schneider, J.A.3
-
44
-
-
34848864297
-
In vitro characterization of Pittsburgh compound-B binding to lewy bodies
-
DOI 10.1523/JNEUROSCI.0630-07.2007
-
Fodero-Tavoletti MT, Smith DP, McLean CA, et al. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci 2007;27(39):10365-71 (Pubitemid 47502018)
-
(2007)
Journal of Neuroscience
, vol.27
, Issue.39
, pp. 10365-10371
-
-
Fodero-Tavoletti, M.T.1
Smith, D.P.2
McLean, C.A.3
Adlard, P.A.4
Barnham, K.J.5
Foster, L.E.6
Leone, L.7
Perez, K.8
Cortes, M.9
Culvenor, J.G.10
Li, Q.-X.11
Laughton, K.M.12
Rowe, C.C.13
Masters, C.L.14
Cappai, R.15
Villemagne, V.L.16
-
45
-
-
34848885454
-
PIB is a non-specific imaging marker of amyloid-beta (Aβ) peptide-related cerebral amyloidosis
-
DOI 10.1093/brain/awm191
-
Lockhart A, Lamb JR, Osredkar T, et al. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain 2007;130(10):2607-15 (Pubitemid 47511709)
-
(2007)
Brain
, vol.130
, Issue.10
, pp. 2607-2615
-
-
Lockhart, A.1
Lamb, J.R.2
Osredkar, T.3
Sue, L.I.4
Joyce, J.N.5
Ye, L.6
Libri, V.7
Leppert, D.8
Beach, T.G.9
-
46
-
-
77955474542
-
The Alzheimers disease neuroimaging initiative positron emission tomography core
-
Jagust WJ, Bandy D, Chen K, et al. The Alzheimers disease neuroimaging initiative positron emission tomography core. Alzheimers Dement 2010;6(3):221-9
-
(2010)
Alzheimers Dement
, vol.6
, Issue.3
, pp. 221-9
-
-
Jagust, W.J.1
Bandy, D.2
Chen, K.3
-
47
-
-
55949117032
-
Frequent amyloid deposition without significant cognitive impairment among the elderly
-
Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008;65(11):1509-17
-
(2008)
Arch Neurol
, vol.65
, Issue.11
, pp. 1509-17
-
-
Aizenstein, H.J.1
Nebes, R.D.2
Saxton, J.A.3
-
48
-
-
39749108812
-
11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment
-
DOI 10.1093/brain/awm336
-
Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimers disease and amnestic mild cognitive impairment. Brain 2008;131(3):665-80 (Pubitemid 351294719)
-
(2008)
Brain
, vol.131
, Issue.3
, pp. 665-680
-
-
Jack Jr., C.R.1
Lowe, V.J.2
Senjem, M.L.3
Weigand, S.D.4
Kemp, B.J.5
Shiung, M.M.6
Knopman, D.S.7
Boeve, B.F.8
Klunk, W.E.9
Mathis, C.A.10
Petersen, R.C.11
-
49
-
-
33747048954
-
11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease
-
DOI 10.1212/01.wnl.0000228230.26044.a4, PII 0000611420060808000020
-
Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006;67(3):446-52 (Pubitemid 44214969)
-
(2006)
Neurology
, vol.67
, Issue.3
, pp. 446-452
-
-
Mintun, M.A.1
Larossa, G.N.2
Sheline, Y.I.3
Dence, C.S.4
Lee, S.Y.5
MacH, R.H.6
Klunk, W.E.7
Mathis, C.A.8
Dekosky, S.T.9
Morris, J.C.10
-
50
-
-
66549127860
-
Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects
-
Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009;132(Pt 5):1310-23
-
(2009)
Brain
, vol.132
, Issue.PART 5
, pp. 1310-23
-
-
Mormino, E.C.1
Kluth, J.T.2
Madison, C.M.3
-
51
-
-
35648932901
-
β-amyloid imaging and memory in non-demented individuals: Evidence for preclinical Alzheimer's disease
-
DOI 10.1093/brain/awm238
-
Pike KE, Savage G, Villemagne VL, et al. beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimers disease. Brain 2007;130(11):2837-44 (Pubitemid 350033975)
-
(2007)
Brain
, vol.130
, Issue.11
, pp. 2837-2844
-
-
Pike, K.E.1
Savage, G.2
Villemagne, V.L.3
Ng, S.4
Moss, S.A.5
Maruff, P.6
Mathis, C.A.7
Klunk, W.E.8
Masters, C.L.9
Rowe, C.C.10
-
52
-
-
66149084048
-
Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimers disease
-
Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimers disease. Proc Natl Acad Sci USA 2009;106(16):6820-5
-
(2009)
Proc Natl Acad Sci USA
, vol.106
, Issue.16
, pp. 6820-5
-
-
Reiman, E.M.1
Chen, K.2
Liu, X.3
-
53
-
-
79551495391
-
Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease
-
Villemagne VL, Pike KE, Chetelat G, et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 2011;69(1):181-92
-
(2011)
Ann Neurol
, vol.69
, Issue.1
, pp. 181-92
-
-
Villemagne, V.L.1
Pike, K.E.2
Chetelat, G.3
-
54
-
-
77954033257
-
Amyloid imaging results from the Australian Imaging Biomarkers and Lifestyle (AIBL) study of aging
-
Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010;31(8):1275-83
-
(2010)
Neurobiol Aging
, vol.31
, Issue.8
, pp. 1275-83
-
-
Rowe, C.C.1
Ellis, K.A.2
Rimajova, M.3
-
55
-
-
72049130805
-
Hypothetical model of dynamic biomarkers of the Alzheimers pathological cascade
-
Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimers pathological cascade. Lancet Neurol 2010;9(1):119-28
-
(2010)
Lancet Neurol
, vol.9
, Issue.1
, pp. 119-28
-
-
Jack, Jr.C.R.1
Knopman, D.S.2
Jagust, W.J.3
-
56
-
-
34248231779
-
PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment
-
DOI 10.1212/01.wnl.0000260969.94695.56, PII 0000611420070508000010
-
Kemppainen NM, Aalto S, Wilson IA, et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 2007;68(19):1603-6 (Pubitemid 46717985)
-
(2007)
Neurology
, vol.68
, Issue.19
, pp. 1603-1606
-
-
Kemppainen, N.M.1
Aalto, S.2
Wilson, I.A.3
Nagren, K.4
Helin, S.5
Bruck, A.6
Oikonen, V.7
Kailajarvi, M.8
Scheinin, M.9
Viitanen, M.10
Parkkola, R.11
Rinne, J.O.12
-
57
-
-
78650415960
-
Positron emission tomography with Pittsburgh compound B in diagnosis of early stage Alzheimers disease
-
Jia J, Sun B, Guo Z, et al. Positron emission tomography with Pittsburgh compound B in diagnosis of early stage Alzheimers disease. Cell Biochem Biophys 2011;59(1):57-62
-
(2011)
Cell Biochem Biophys
, vol.59
, Issue.1
, pp. 57-62
-
-
Jia, J.1
Sun, B.2
Guo, Z.3
-
58
-
-
77957257228
-
Clinically different stages of Alzheimers disease associated by amyloid deposition with [11C]-PIB PET imaging
-
Hatashita S, Yamasaki H. Clinically different stages of Alzheimers disease associated by amyloid deposition with [11C]-PIB PET imaging. J Alzheimers Dis 2010;21(3):995-1003
-
(2010)
J Alzheimers Dis
, vol.21
, Issue.3
, pp. 995-1003
-
-
Hatashita, S.1
Yamasaki, H.2
-
59
-
-
77955528206
-
Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls
-
Devanand DP, Mikhno A, Pelton GH, et al. Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls. J Geriatr Psychiatry Neurol 2010;23(3):185-98
-
(2010)
J Geriatr Psychiatry Neurol
, vol.23
, Issue.3
, pp. 185-98
-
-
Devanand, D.P.1
Mikhno, A.2
Pelton, G.H.3
-
60
-
-
49349092320
-
PET imaging of amyloid deposition in patients with mild cognitive impairment
-
Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008;29(10):1456-65
-
(2008)
Neurobiol Aging
, vol.29
, Issue.10
, pp. 1456-65
-
-
Forsberg, A.1
Engler, H.2
Almkvist, O.3
-
61
-
-
66549106850
-
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimers disease: Implications for sequence of pathological events in Alzheimers disease
-
Jack CR, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimers disease: implications for sequence of pathological events in Alzheimers disease. Brain 2009;132(5):1355-65
-
(2009)
Brain
, vol.132
, Issue.5
, pp. 1355-65
-
-
Jack, C.R.1
Lowe, V.J.2
Weigand, S.D.3
-
62
-
-
33749506795
-
Two-year follow-up of amyloid deposition in patients with Alzheimer's disease
-
DOI 10.1093/brain/awl178
-
Engler H, Forsberg A, Almkvist O, et al. Two-year follow-up of amyloid deposition in patients with Alzheimers disease. Brain 2006;129(11):2856-66 (Pubitemid 44684508)
-
(2006)
Brain
, vol.129
, Issue.11
, pp. 2856-2866
-
-
Engler, H.1
Forsberg, A.2
Almkvist, O.3
Blomquist, G.4
Larsson, E.5
Savitcheva, I.6
Wall, A.7
Ringheim, A.8
Langstrom, B.9
Nordberg, A.10
-
63
-
-
85058205144
-
Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimers disease
-
In press
-
Kadir A, Almkvist O, Forsberg A, et al. Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimers disease. Neurobiol Aging; In press
-
Neurobiol Aging
-
-
Kadir, A.1
Almkvist, O.2
Forsberg, A.3
-
64
-
-
70350164263
-
Follow-up of [11C]. PIB uptake and brain volume in patients with Alzheimer disease and controls
-
Scheinin NM, Aalto S, Koikkalainen J, et al. Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology 2009;73(15):1186-92
-
(2009)
Neurology
, vol.73
, Issue.15
, pp. 1186-92
-
-
Scheinin, N.M.1
Aalto, S.2
Koikkalainen, J.3
-
65
-
-
77949300796
-
(11)C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimers disease treated with bapineuzumab: A phase 2 double-blind placebo-controlled ascending-dose study
-
Rinne JO, Brooks DJ, Rossor MN, et al. (11)C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimers disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9(4):363-72
-
(2010)
Lancet Neurol
, vol.9
, Issue.4
, pp. 363-72
-
-
Rinne, J.O.1
Brooks, D.J.2
Rossor, M.N.3
-
66
-
-
78049427912
-
Progression of cerebral amyloid load is associated with the apolipoprotein e epsilon4 genotype in Alzheimers disease
-
Grimmer T, Tholen S, Yousefi BH, et al. Progression of cerebral amyloid load is associated with the apolipoprotein E epsilon4 genotype in Alzheimers disease. Biol Psychiatry 2010;68(10):879-84
-
(2010)
Biol Psychiatry
, vol.68
, Issue.10
, pp. 879-84
-
-
Grimmer, T.1
Tholen, S.2
Yousefi, B.H.3
-
67
-
-
79953177902
-
Amyloid PET imaging in patients with mild cognitive impairment
-
Koivunen J, Scheinin N, Virta JR, et al. Amyloid PET imaging in patients with mild cognitive impairment. Neurology 2011;76:1085-90
-
(2011)
Neurology
, vol.76
, pp. 1085-90
-
-
Koivunen, J.1
Scheinin, N.2
Virta, J.R.3
-
68
-
-
73549106106
-
Cognitive decline and brain volume loss as signatures of cerebral Amyloid-beta peptide deposition identified with Pittsburgh compound B: Cognitive decline associated with Abeta deposition
-
Storandt M, Mintun MA, Head D, Morris JC. Cognitive decline and brain volume loss as signatures of cerebral Amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol 2009;66(12):1476-81
-
(2009)
Arch Neurol
, vol.66
, Issue.12
, pp. 1476-81
-
-
Storandt, M.1
Mintun, M.A.2
Head, D.3
Morris, J.C.4
-
69
-
-
77949701876
-
High PIB retention in Alzheimers disease is an early event with complex relationship with CSF biomarkers and functional parameters
-
Forsberg A, Almkvist O, Engler H, et al. High PIB retention in Alzheimers disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr Alzheimer Res 2010;7(1):56-66
-
(2010)
Curr Alzheimer Res
, vol.7
, Issue.1
, pp. 56-66
-
-
Forsberg, A.1
Almkvist, O.2
Engler, H.3
-
70
-
-
77954033982
-
3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects
-
Apostolova LG, Hwang KS, Andrawis JP, et al. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging 2010;31(8):1284-303
-
(2010)
Neurobiol Aging
, vol.31
, Issue.8
, pp. 1284-303
-
-
Apostolova, L.G.1
Hwang, K.S.2
Andrawis, J.P.3
-
71
-
-
80053638033
-
Lack of association between 11C-PiB and longitudinal brain atrophy in non-demented older individuals
-
In press
-
Driscoll I, Zhou Y, An Y, et al. Lack of association between 11C-PiB and longitudinal brain atrophy in non-demented older individuals. Neurobiol Aging; In press
-
Neurobiol Aging
-
-
Driscoll, I.1
Zhou, Y.2
An, Y.3
-
72
-
-
77950535797
-
Relationship between atrophy and beta-amyloid deposition in Alzheimer disease
-
Chetelat G, Villemagne VL, Bourgeat P, et al. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol 2010;67(3):317-24
-
(2010)
Ann Neurol
, vol.67
, Issue.3
, pp. 317-24
-
-
Chetelat, G.1
Villemagne, V.L.2
Bourgeat, P.3
-
73
-
-
33749150163
-
Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry
-
DOI 10.1007/s00401-006-0127-z
-
Braak H, Alafuzoff I, Arzberger T, et al. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol (Berl) 2006;112(4):389-404 (Pubitemid 44469160)
-
(2006)
Acta Neuropathologica
, vol.112
, Issue.4
, pp. 389-404
-
-
Braak, H.1
Alafuzoff, I.2
Arzberger, T.3
Kretzschmar, H.4
Tredici, K.5
-
74
-
-
70349582720
-
Conversion of amyloid positive and negative MCI to AD over 3 years
-
Okello A, Koivunen J, Edison P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years. Neurology 2009;73(10):754-60
-
(2009)
Neurology
, vol.73
, Issue.10
, pp. 754-60
-
-
Okello, A.1
Koivunen, J.2
Edison, P.3
-
75
-
-
53849132759
-
PET amyloid ligand [11C]. PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment
-
Koivunen J, Pirttila T, Kemppainen N, et al. PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. Dement Geriatr Cogn Disord 2008;26(4):378-83
-
(2008)
Dement Geriatr Cogn Disord
, vol.26
, Issue.4
, pp. 378-83
-
-
Koivunen, J.1
Pirttila, T.2
Kemppainen, N.3
-
76
-
-
73549092137
-
Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease
-
Morris JC, Roe CM, Grant EA, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009;66(12):1469-75
-
(2009)
Arch Neurol
, vol.66
, Issue.12
, pp. 1469-75
-
-
Morris, J.C.1
Roe, C.M.2
Grant, E.A.3
-
77
-
-
67249121764
-
Amyloid imaging in mild cognitive impairment subtypes
-
Wolk DA, Price JC, Saxton JA, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 2009;65(5):557-68
-
(2009)
Ann Neurol
, vol.65
, Issue.5
, pp. 557-68
-
-
Wolk, D.A.1
Price, J.C.2
Saxton, J.A.3
-
78
-
-
4544335597
-
Mild cognitive impairment as a diagnostic entity
-
DOI 10.1111/j.1365-2796.2004.01388.x
-
Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256(3):183-94. Available from: www.adni-info.org (Pubitemid 39222988)
-
(2004)
Journal of Internal Medicine
, vol.256
, Issue.3
, pp. 183-194
-
-
Petersen, R.C.1
-
80
-
-
77953340628
-
In vivo amyloid deposition and neuropathological findings after humanized amyloid beta-specific monoclonal antibodies therapy in a patient with Alzheimers disease
-
Lopez OL, Hamilton R, Ikonomovic M, et al. In vivo amyloid deposition and neuropathological findings after humanized amyloid beta-specific monoclonal antibodies therapy in a patient with Alzheimers disease. Alzheimers Dement 2009;5(4):P64-5
-
(2009)
Alzheimers Dement
, vol.5
, Issue.4
-
-
Lopez, O.L.1
Hamilton, R.2
Ikonomovic, M.3
-
81
-
-
77955704022
-
Integrating ADNI results into Alzheimers disease drug development programs
-
Cummings JL. Integrating ADNI results into Alzheimers disease drug development programs. Neurobiol Aging 2010;31(8):1481-92
-
(2010)
Neurobiol Aging
, vol.31
, Issue.8
, pp. 1481-92
-
-
Cummings, J.L.1
-
82
-
-
77954028812
-
Enrichment through biomarkers in clinical trials of Alzheimers drugs in patients with mild cognitive impairment
-
e1
-
Lorenzi M, Donohue M, Paternico D, et al. Enrichment through biomarkers in clinical trials of Alzheimers drugs in patients with mild cognitive impairment. Neurobiol Aging 2010;31(8):1443-51; e1
-
(2010)
Neurobiol Aging
, vol.31
, Issue.8
, pp. 1443-51
-
-
Lorenzi, M.1
Donohue, M.2
Paternico, D.3
-
83
-
-
11444267243
-
Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD
-
Bayer AJ, Bullock R, Jones RW, et al. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 2005;64(1):94-101 (Pubitemid 40082943)
-
(2005)
Neurology
, vol.64
, Issue.1
, pp. 94-101
-
-
Bayer, A.J.1
Bullock, R.2
Jones, R.W.3
Wilkinson, D.4
Paterson, K.R.5
Jenkins, L.6
Millais, S.B.7
Donoghue, S.8
-
84
-
-
20944448555
-
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
-
DOI 10.1212/01.WNL.0000159740.16984.3C
-
Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64(9):1553-62 (Pubitemid 40617691)
-
(2005)
Neurology
, vol.64
, Issue.9
, pp. 1553-1562
-
-
Gilman, S.1
Koller, M.2
Black, R.S.3
Jenkins, L.4
Griffith, S.G.5
Fox, N.C.6
Eisner, L.7
Kirby, L.8
Boada Rovira, M.9
Forette, F.10
Orgogozo, J.-M.11
-
85
-
-
47149112621
-
42 immunisation in Alzheimer's disease: Follow-up of a randomised, placebo-controlled phase I trial
-
DOI 10.1016/S0140-6736(08)61075-2, PII S0140673608610752
-
Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimers disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008;372(9634):216-23 (Pubitemid 351978111)
-
(2008)
The Lancet
, vol.372
, Issue.9634
, pp. 216-223
-
-
Holmes, C.1
Boche, D.2
Wilkinson, D.3
Yadegarfar, G.4
Hopkins, V.5
Bayer, A.6
Jones, R.W.7
Bullock, R.8
Love, S.9
Neal, J.W.10
Zotova, E.11
Nicoll, J.A.12
-
86
-
-
52449089987
-
Thirty years of Alzheimers disease genetics: The implications of systematic meta-analyses
-
Bertram L, Tanzi RE. Thirty years of Alzheimers disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci 2008;9(10):768-78
-
(2008)
Nat Rev Neurosci
, vol.9
, Issue.10
, pp. 768-78
-
-
Bertram, L.1
Tanzi, R.E.2
-
87
-
-
68249134074
-
The role of apolipoprotein e in Alzheimers disease
-
Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimers disease. Neuron 2009;63(3):287-303
-
(2009)
Neuron
, vol.63
, Issue.3
, pp. 287-303
-
-
Kim, J.1
Basak, J.M.2
Holtzman, D.M.3
-
88
-
-
77649314191
-
APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging
-
Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010;67(1):122-31
-
(2010)
Ann Neurol
, vol.67
, Issue.1
, pp. 122-31
-
-
Morris, J.C.1
Roe, C.M.2
Xiong, C.3
-
89
-
-
67549147148
-
Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease
-
Drzezga A, Grimmer T, Henriksen G, et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 2009;72(17):1487-94
-
(2009)
Neurology
, vol.72
, Issue.17
, pp. 1487-94
-
-
Drzezga, A.1
Grimmer, T.2
Henriksen, G.3
-
90
-
-
34248579291
-
Imaging β-amyloid burden in aging and dementia
-
DOI 10.1212/01.wnl.0000261919.22630.ea, PII 0000611420070515000012
-
Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007;68(20):1718-25 (Pubitemid 46763260)
-
(2007)
Neurology
, vol.68
, Issue.20
, pp. 1718-1725
-
-
Rowe, C.C.1
Ng, S.2
Ackermann, U.3
Gong, S.J.4
Pike, K.5
Savage, G.6
Cowie, T.F.7
Dickinson, K.L.8
Maruff, P.9
Darby, D.10
Smith, C.11
Woodward, M.12
Merory, J.13
Tochon-Danguy, H.14
O'Keefe, G.15
Klunk, W.E.16
Mathis, C.A.17
Price, J.C.18
Masters, C.L.19
Villemagne, V.L.20
more..
-
91
-
-
77949555201
-
Pittsburgh compound-B and Alzheimers disease biomarkers in CSF plasma and urine: An exploratory study
-
Degerman Gunnarsson M, Lindau M, Wall A, et al. Pittsburgh compound-B and Alzheimers disease biomarkers in CSF, plasma and urine: an exploratory study. Dement Geriatr Cogn Disord 2010;29(3):204-12
-
(2010)
Dement Geriatr Cogn Disord
, vol.29
, Issue.3
, pp. 204-12
-
-
Degerman Gunnarsson, M.1
Lindau, M.2
Wall, A.3
-
92
-
-
77149159754
-
Cortical binding of Pittsburgh compound B an endophenotype for genetic studies of Alzheimers disease
-
Hinrichs AL, Mintun MA, Head D, et al. Cortical binding of Pittsburgh compound B, an endophenotype for genetic studies of Alzheimers disease. Biol Psychiatry 2010;67(6):581-3
-
(2010)
Biol Psychiatry
, vol.67
, Issue.6
, pp. 581-3
-
-
Hinrichs, A.L.1
Mintun, M.A.2
Head, D.3
-
93
-
-
77950546575
-
Increased fibrillar amyloid-beta burden in normal individuals with a family history of late-onset Alzheimers
-
Mosconi L, Rinne JO, Tsui WH, et al. Increased fibrillar amyloid-beta burden in normal individuals with a family history of late-onset Alzheimers. Proc Natl Acad Sci USA 2010;107(13):5949-54
-
(2010)
Proc Natl Acad Sci USA
, vol.107
, Issue.13
, pp. 5949-54
-
-
Mosconi, L.1
Rinne, J.O.2
Tsui, W.H.3
-
94
-
-
65249159879
-
Cerebrospinal fluid biomarker signature in Alzheimers disease neuroimaging initiative subjects
-
Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimers disease neuroimaging initiative subjects. Ann Neurol 2009;65(4):403-13
-
(2009)
Ann Neurol
, vol.65
, Issue.4
, pp. 403-13
-
-
Shaw, L.M.1
Vanderstichele, H.2
Knapik-Czajka, M.3
-
95
-
-
77949425172
-
Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimers disease
-
Fagan AM, Mintun MA, Shah AR, et al. Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimers disease. EMBO Mol Med 2009;1(8-9):371-80
-
(2009)
EMBO Mol Med
, vol.1
, Issue.8-9
, pp. 371-80
-
-
Fagan, A.M.1
Mintun, M.A.2
Shah, A.R.3
-
96
-
-
70350152831
-
Relationships between biomarkers in aging and dementia
-
Jagust WJ, Landau SM, Shaw LM, et al. Relationships between biomarkers in aging and dementia. Neurology 2009;73(15):1193-9
-
(2009)
Neurology
, vol.73
, Issue.15
, pp. 1193-9
-
-
Jagust, W.J.1
Landau, S.M.2
Shaw, L.M.3
-
97
-
-
69449085355
-
Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding
-
Tolboom N, van der Flier WM, Yaqub M, et al. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J Nucl Med 2009;50(9):1464-70
-
(2009)
J Nucl Med
, vol.50
, Issue.9
, pp. 1464-70
-
-
Tolboom, N.1
Van Der Flier, W.M.2
Yaqub, M.3
-
98
-
-
67349227896
-
Beta amyloid in Alzheimers disease: Increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid
-
Grimmer T, Riemenschneider M, Forstl H, et al. Beta amyloid in Alzheimers disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 2009;65(11):927-34
-
(2009)
Biol Psychiatry
, vol.65
, Issue.11
, pp. 927-34
-
-
Grimmer, T.1
Riemenschneider, M.2
Forstl, H.3
-
99
-
-
33644832047
-
42 in humans
-
DOI 10.1002/ana.20730
-
Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006;59(3):512-19 (Pubitemid 43358072)
-
(2006)
Annals of Neurology
, vol.59
, Issue.3
, pp. 512-519
-
-
Fagan, A.M.1
Mintun, M.A.2
Mach, R.H.3
Lee, S.-Y.4
Dence, C.S.5
Shah, A.R.6
LaRossa, G.N.7
Spinner, M.L.8
Klunk, W.E.9
Mathis, C.A.10
DeKosky, S.T.11
Morris, J.C.12
Holtzman, D.M.13
-
100
-
-
79952740168
-
Transforming cerebrospinal fluid Abeta42 measures into calculated Pittsburgh compound B units of brain A [beta] amyloid
-
Weigand SD, Vemuri P, Wiste HJ, et al. Transforming cerebrospinal fluid Abeta42 measures into calculated Pittsburgh compound B units of brain A [beta] amyloid. Alzheimers Dement 2011;7(2):133-41
-
(2011)
Alzheimers Dement
, vol.7
, Issue.2
, pp. 133-41
-
-
Weigand, S.D.1
Vemuri, P.2
Wiste, H.J.3
-
101
-
-
73549123897
-
Absence of Pittsburgh compound B detection of cerebral amyloid-beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: A case report
-
Cairns NJ, Ikonomovic MD, Benzinger T, et al. Absence of Pittsburgh compound B detection of cerebral amyloid-beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol 2009;66(12):1557-62
-
(2009)
Arch Neurol
, vol.66
, Issue.12
, pp. 1557-62
-
-
Cairns, N.J.1
Ikonomovic, M.D.2
Benzinger, T.3
-
103
-
-
34248190279
-
A-beta oligomers: A decade of discovery
-
Walsh DM, Selkoe DJ. A-beta oligomers: a decade of discovery. J Neurochem 2007;101(5):1172-84
-
(2007)
J Neurochem
, vol.101
, Issue.5
, pp. 1172-84
-
-
Walsh, D.M.1
Selkoe, D.J.2
-
104
-
-
77958522371
-
Hippocampal CA1 apical neuropil atrophy in mild Alzheimer disease visualized with 7-T MRI
-
Kerchner GA, Hess CP, Hammond-Rosenbluth KE, et al. Hippocampal CA1 apical neuropil atrophy in mild Alzheimer disease visualized with 7-T MRI. Neurology 2010;75(15):1381-7
-
(2010)
Neurology
, vol.75
, Issue.15
, pp. 1381-7
-
-
Kerchner, G.A.1
Hess, C.P.2
Hammond-Rosenbluth, K.E.3
-
105
-
-
79953651513
-
18F-THK523: A novel in vivo tau imaging ligand for Alzheimers disease
-
Fodero-Tavoletti MT, Okamura N, Furumoto S, et al. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimers disease. Brain 2011;134(4):1089-100
-
(2011)
Brain
, vol.134
, Issue.4
, pp. 1089-100
-
-
Fodero-Tavoletti, M.T.1
Okamura, N.2
Furumoto, S.3
-
106
-
-
80054891673
-
Discovery of Novel [18F]-PET Agents for Imaging Neurofibrillary Tangles (NFTs)
-
Paris France
-
Kolb H. Discovery of Novel [18F]-PET Agents for Imaging Neurofibrillary Tangles (NFTs). Alzheimers Association International Conference. Paris, France, 2011
-
(2011)
Alzheimers Association International Conference
-
-
Kolb, H.1
|